Press Release Details

Cerus Announces Belgian Contract for Intercept Platelet System

April, 14 2009

CONCORD, Calif.--(BUSINESS WIRE)--Apr. 14, 2009-- Cerus Corporation (NASDAQ:CERS) announced today that the Belgian Red Cross, Service Francophone du Sang (SFS), has signed a contract to purchase the INTERCEPT platelet system. The SFS is one of two major Red Cross blood services in Belgium, supplying blood to the Wallonia region and part of Brussels, with principal blood centers in Brabant-Hainaut, Liège, and Namur. Approximately 30% of Belgium’s platelet components, an estimated 17,500 units annually, are produced by the SFS.

“Cerus commends the SFS on their commitment to providing improved protection for platelet transfusion recipients,” said Claes Glassell, president and CEO of Cerus Corporation. “We believe the Belgian Red Cross chose to sign a contract with us prior to finalization of official governmental reimbursement because of the safety benefits inherent in the INTERCEPT Blood System. This is another key development in the commercialization of the INTERCEPT Blood System in Europe.”

Use of pathogen inactivation for transfused plasma was mandated in Belgium in 2007, and in 2008 the High Council of Health issued a recommendation for universal implementation of pathogen-inactivated platelets to reduce the risk of transfusion-transmitted infections. The INTERCEPT platelet system is already used by Belgian blood centers in Yvoir, Brugge, and Charleroi, and also by the Belgian Army blood service.

ABOUT THE INTERCEPT BLOOD SYSTEM

The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of known and emerging pathogens, including viruses, bacteria and parasites, as well as harmful white blood cells that may be present in donated blood intended for transfusion. The system inactivates pathogens using a proprietary illumination device, process and active compound. The INTERCEPT Blood System is designed for easy integration with routine blood center operations, and treated platelets are approved for storage up to seven days according to local guidelines. The INTERCEPT Blood System has received CE mark approvals for both the platelet and plasma systems, and may replace gamma irradiation for protection against transfusion-associated graft-vs-host disease. The INTERCEPT Blood System has customers in 18 countries.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation
Lainie Corten, 925-288-6319
Marketing Director

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600